 | |
- close
- close
| |||||||||
Industry (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
 |
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
 |
|
| Operating Income | |
0 | 0 | 0 | 0 | 0 | |
|
| Gross Profit | |
19.4B | 18.6B | 18.9B | 20.0B | 19.9B | |
|
| Total Revenues | |
22.9B | 22.0B | 22.6B | 24.2B | 23.9B | |
|
| Net Income | |
5.81B | 4.63B | 4.43B | 3.28B | 7.81B | |
|
| Gross Margin | |
78.4% | 76.6% | 73.5% | 74.6% | 76.6% |   | |
| Research and Development Expense | |
4.01B | 3.85B | 4.78B | 4.88B | 4.81B | | |
| R&D/Sales Ratio | |
17.5% | 17.5% | 21.1% | 20.2% | 20.1% | | |
| Number of Patents | |
0 | 0 | 0 | 0 | 19.0 | | |
| Patents to Expire in next 5 years | |
0 | 0 | 0 | 8.00 | 7.00 | | |
| Number of Drugs in Phase I | |
0 | 25.0 | 29.0 | 23.0 | 22.0 | | |
| Number of Drugs in Phase II | |
0 | 15.0 | 20.0 | 17.0 | 16.0 | | |
| Number of Drugs in Phase III | |
0 | 6.00 | 5.00 | 7.00 | 9.00 | | |
| Number of Drug Approvals | |
0 | 2.00 | 5.00 | 2.00 | 1.00 | | |
| New Drug Applications | |
0 | 3.00 | 0 | 2.00 | 0 | | |
| ||||||
|
|
